Skip to main content
OpenTrials
Completed

NCT Number: NCT02294747

Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA

Trochanteric fractures represent about half of the hip fractures (with femoral neck fractures as the other half). Trochanteric hip fractures are almost always treated surgically with internal fixation of the fracture. However there is a debate ongoing for what is the appropriate implant to use. For stable fracture patterns the evidence seems to be in favor of the sliding hip screw, but for the unstable fractures it is more unclear whether to use a intramedullary nail or sliding hip screw with or without a lateral support plate (TSP). The role of the TSP in clinical use remains unclear and very little has been published about this, but it is believed to be an important contributor of stability to the sliding hip screw construct. We are planning a randomized controlled trial on trochanteric hip fractures to establish a method for implanting the tantalum markers, to observe the fracture healing process and to further investigate the role of the TSP.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Diakonhjemmet Hospital, Oslo, Norway

Loading trial locations.

About this study

Trochanteric fractures represent about half of the hip fractures (with femoral neck fractures as the other half), and are almost always treated surgically with internal fixation of the fracture. However, there is an ongoing debate on what is the appropriate implant to use. For stable fracture patterns the evidence seems to be in favour of the sliding hip screw, whereas for the unstable fractures it is unclear whether an intramedullary nail or a sliding hip screw with or without a lateral support plate should be the implant of choice. A series of studies is now planned at Oslo University Hospital in collaboration with Diakonhjemmet Hospital in hope to further clarify this debate. The use of the lateral/trochanteric support plate (TSP) is widespread in some regions (e.g. Norway, Sweden and parts of Britain), but virtually never used other places. The role of the TSP remains unclear and very little has been published on it's use, even though it is believed to be an important contributor of stability to the sliding hip screw construct.

Trochanteric fractures are mainly caused by a direct trauma, i.e mainly a fall from own height in the elderly. The fractures are most often classified using the Müller AO classification or the Evans/Jensen, but several other classification systems also exist. The ideal classification system should be easily applicable, reliable, and aid in treatment decision making.

The treatment of trochanteric fractures comprise perioperative and operative modalities. The perioperative modalities consist among others of medical optimalization preoperatively, early rehabilitation and prevention of new fractures by treating osteoporosis and preventing new falls. The main scope of the current study will, however, be the operative modalities.

Surgery for trochanteric fractures is performed mainly with fracture reduction on a traction table and internal fixation, using either an intramedullary (IM) nail or a sliding hip screw (SHS), both available in various designs from different manufacturers. The latest Cochrane review did not conclude on which implant is the superior. However, among stable fractures there are less reoperations with the SHS, mainly due to peri-implant femoral fractures after operation with an IM nail that. The more unstable fractures, namely the reverse oblique and subtrochanteric fractures, may obtain better results using an intramedullary nail, probably due to less secondary dislocations with resulting varus deformity, shaft-medialization and shortening. The evidence for this is, however, weak and the role of the TSP remains unclear.

Radiostereometry (RSA) is the most precise and accurate method to measure motion in vivo between different segments in orthopaedic research. To do so, radio-opaque tantalum markers are implanted into the bone defining different segments. Stereoradiographs are performed over time to detect movement and monitor the healing (or non healing) process. This movement can be calculated both as translations and rotations. They are ideal to describe and compare the stability of fracture systems. RSA has been used successfully in earlier studies on fracture healing. Due to the high accuracy and precision, RSA yield reliable results with relatively small study-groups. We plan to use RSA to measure fracture dislocation and time to healing in our studies.

The study will be on the function of the trochanteric support plate and it´s ability to prevent secondary dislocation in AO 31 A2 fractures. We will utilize RSA for measurements during follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • AO 31-A2
  • able to walk independently, aids such as crutches or walker allowed
  • able to consent
  • fit for surgery with SHS with or without TSP

Exclusion criteria

  • not willing or able to attain follow up
  • previous fracture or surgery with retained metal work in the same hip
  • concomitant disease that will shorten life expectancy

Treatment and study plan

Sliding Hip Screw with Trochanteric Stabilization Plate

Device

Other names: Lateral Stabilizing Plate, Lateral Support Shield

Sliding Hip Screw without Trochanteric Stabilization Plate

Device

Primary outcomes

  1. Fracture displacement during healing measured with radiostereometry

    Time frame: 52 weeks

    Will be measured by RSA postoperatively, before discharge and after 4, 8, 12, 24 and 52 weeks. Total displacement from first reading to the reading showing maximum displacement is the main outcome.

Secondary outcomes

  1. Perioperative blood loss

    Time frame: 1 week

  2. Time of surgery

    Time frame: 1 week

  3. Eq5d

    Time frame: 52 weeks

    Health Related Quality of Life (Hrqol).

  4. Eq5d

    Time frame: 26 weeks

    Hrqol.

  5. Eq5d

    Time frame: 12 weeks

    Hrqol.

  6. Eq5d

    Time frame: 8 weeks

    Hrqol.

  7. Eq5d

    Time frame: 4 weeks

    Hrqol.

  8. Time to union as measured by RSA (cessation of motion) and radiographs

    Time frame: Will be examined at 4, 8, 12, 26 and 52 weeks

    When RSA shows that no motion has happened between two time points the fracture will be regarded as healed at the former time point.

  9. Time to union as measured by plain radiographs and clinical findings

    Time frame: Will be examined at 4, 8, 12, 26 and 52 weeks

    Composite endpoint: Healing defined by obliteration of fracture line radiographically and pain free weight bearing (except lateral pain from hardware), when this occurs the fracture will be considered healed.

  10. Harris Hip Score

    Time frame: 52 weeks

    Will be examined at 4, 8, 12, 26 and 52 weeks

  11. Harris Hip Score

    Time frame: 26 weeks

    Will be examined at 4, 8, 12, 26 and 52 weeks

  12. Harris Hip Score

    Time frame: 12 weeks

    Will be examined at 4, 8, 12, 26 and 52 weeks

  13. Harris Hip Score

    Time frame: 8 weeks

    Will be examined at 4, 8, 12, 26 and 52 weeks

  14. Harris Hip Score

    Time frame: 4 weeks

    Will be examined at 4, 8, 12, 26 and 52 weeks

  15. Postoperative pain (NRS) while in hospital

    Time frame: 1 week

    Pain at mobilization (NRS) at discharge

  16. Timed Up and Go (Tug) test

    Time frame: 4 weeks

  17. Timed Up and Go (Tug) test

    Time frame: 8 weeks

  18. Timed Up and Go (Tug) test

    Time frame: 12 weeks

  19. Timed Up and Go (Tug) test

    Time frame: 26 weeks

  20. Timed Up and Go (Tug) test

    Time frame: 52 weeks

  21. Pain (NRS)

    Time frame: 4 weeks

    Maximum hip pain during the last week

  22. Pain (NRS)

    Time frame: 8 weeks

    Maximum hip pain during the last week

  23. Pain (NRS)

    Time frame: 12 weeks

    Maximum hip pain during the last week

  24. Pain (NRS)

    Time frame: 26 weeks

    Maximum hip pain during the last week

  25. Pain (NRS)

    Time frame: 52 weeks

    Maximum hip pain during the last week

  26. Satisfaction with operated hip (NRS)

    Time frame: 4 weeks

  27. Satisfaction with operated hip (NRS)

    Time frame: 8 weeks

  28. Satisfaction with operated hip (NRS)

    Time frame: 12 weeks

  29. Satisfaction with operated hip (NRS)

    Time frame: 26 weeks

  30. Satisfaction with operated hip (NRS)

    Time frame: 52 weeks

  31. Motion during healing as measured by radiostereometry.

    Time frame: 52 weeks

    Will be measured by RSA postoperatively, before discharge and after 4, 8, 12, 24 and 52 weeks. Pattern and time of secondary displacement will be compared between the treatment groups during the first year postoperatively.

  32. Motion during healing as measured by plain radiographs.,

    Time frame: 52 weeks

    The rate and degree of secondary displacement during the first year will be compared between the groups.

Other outcomes

  1. Reoperation for healing problems

    Time frame: 52 weeks

    Any additional surgery addressing healing problems or hardware failure

  2. Mortality

    Time frame: 52 weeks

    Any reason

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • Diakonhjemmet Hospital

Registry information

Official study title

Trochanteric Hip Fractures (AO A2) Treated With Sliding Hip Screw With or Without Trochanteric Stabilizing Plate - a Randomized Controlled Trial Using Radiostereometry.

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Nov 19, 2014
Registry last updated
Sep 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.